Theodore S Jardetzky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4150189/publications.pdf

Version: 2024-02-01

77 papers

5,831 citations

38 h-index 73 g-index

81 all docs 81 docs citations

81 times ranked 6883 citing authors

#	Article	IF	CITATIONS
1	Identification of functionally important domains of human cytomegalovirus gO that act after trimer binding to receptors. PLoS Pathogens, 2022, 18, e1010452.	4.7	1
2	The structural basis of herpesvirus entry. Nature Reviews Microbiology, 2021, 19, 110-121.	28.6	174
3	Bottom-up de novo design of functional proteins with complex structural features. Nature Chemical Biology, 2021, 17, 492-500.	8.0	65
4	EphrinB2 clustering by Nipah virus G is required to activate and trap F intermediates at supported lipid bilayer–cell interfaces. Science Advances, 2021, 7, .	10.3	18
5	Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions. Journal of Allergy and Clinical Immunology, 2021, 148, 1049-1060.	2.9	21
6	The role of allergenâ€specific IgE, IgG and IgA in allergic disease. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3627-3641.	5.7	100
7	Accuracy of serological testing for SARSâ€CoVâ€2 antibodies: First results of a large mixedâ€method evaluation study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 853-865.	5.7	34
8	Cryo-Electron Microscopy Structure and Interactions of the Human Cytomegalovirus gHgLgO Trimer with Platelet-Derived Growth Factor Receptor Alpha. MBio, 2021, 12, e0262521.	4.1	2
9	Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host and Microbe, 2021, 29, 1738-1743.e4.	11.0	61
10	Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex. Nature Communications, 2021, 12, 7069.	12.8	6
11	The mechanistic and functional profile of the therapeutic anti-lgE antibody ligelizumab differs from omalizumab. Nature Communications, 2020, 11, 165.	12.8	123
12	Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2. Cell Host and Microbe, 2020, 28, 516-525.e5.	11.0	219
13	Epstein-Barr Virus gH/gL and Kaposi's Sarcoma-Associated Herpesvirus gH/gL Bind to Different Sites on EphA2 To Trigger Fusion. Journal of Virology, 2020, 94, .	3.4	11
14	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 2020, 5, .	11.9	404
15	IPSE, a urogenital parasite-derived immunomodulatory molecule, suppresses bladder pathogenesis and anti-microbial peptide gene expression in bacterial urinary tract infection. Parasites and Vectors, 2020, 13, 615.	2.5	2
16	IPSE, an abundant egg-secreted protein of the carcinogenic helminth Schistosoma haematobium, promotes proliferation of bladder cancer cells and angiogenesis. Infectious Agents and Cancer, 2020, 15, 63.	2.6	15
17	De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science, 2020, 368, .	12.6	137
18	IPSE, a parasite-derived, host immunomodulatory infiltrin protein, alleviates resiniferatoxin-induced bladder pain. Molecular Pain, 2020, 16, 174480692097009.	2.1	1

#	Article	IF	CITATIONS
19	HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3728-3733.	7.1	42
20	Ephrin Receptor A4 is a New Kaposi's Sarcoma-Associated Herpesvirus Virus Entry Receptor. MBio, 2019, 10, .	4.1	34
21	IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. Scientific Reports, 2019, 9, 1586.	3.3	15
22	IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis. American Journal of Physiology - Renal Physiology, 2019, 316, F1133-F1140.	2.7	8
23	Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus. Nature Microbiology, 2018, 3, 172-180.	13.3	157
24	Therapeutic exploitation of IPSE, a urogenital parasiteâ€derived host modulatory protein, for chemotherapyâ€induced hemorrhagic cystitis. FASEB Journal, 2018, 32, 4408-4419.	0.5	21
25	Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nature Microbiology, 2017, 2, 16272.	13.3	65
26	The COMPLEXity in herpesvirus entry. Current Opinion in Virology, 2017, 24, 97-104.	5.4	74
27	Monomeric ephrinB2 binding induces allosteric changes in Nipah virus G that precede its full activation. Nature Communications, 2017, 8, 781.	12.8	38
28	H-IPSE Is a Pathogen-Secreted Host Nucleus-Infiltrating Protein (Infiltrin) Expressed Exclusively by the Schistosoma haematobium Egg Stage. Infection and Immunity, 2017, 85, .	2.2	29
29	Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8703-E8710.	7.1	27
30	Epstein-Barr Virus Fusion with Epithelial Cells Triggered by gB Is Restricted by a gL Glycosylation Site. Journal of Virology, 2017, 91, .	3.4	16
31	Editorial overview: Virus structure and functions. Current Opinion in Virology, 2017, 24, ix.	5.4	1
32	Immobilization of the N-terminal helix stabilizes prefusion paramyxovirus fusion proteins. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3844-51.	7.1	4
33	Structural basis for Epstein–Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins. Nature Communications, 2016, 7, 13557.	12.8	79
34	The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment. MBio, 2016, 7, .	4.1	14
35	Comparative Mutagenesis of Pseudorabies Virus and Epstein-Barr Virus gH Identifies a Structural Determinant within Domain III of gH Required for Surface Expression and Entry Function. Journal of Virology, 2016, 90, 2285-2293.	3.4	5
36	Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6849-E6858.	7.1	38

#	Article	IF	CITATIONS
37	Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nature Communications, 2016, 7, 11610.	12.8	86
38	Mutagenesis of Paramyxovirus Hemagglutinin-Neuraminidase Membrane-Proximal Stalk Region Influences Stability, Receptor Binding, and Neuraminidase Activity. Journal of Virology, 2016, 90, 7778-7788.	3.4	16
39	Structure and stabilization of the Hendra virus F glycoprotein in its prefusion form. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1056-1061.	7.1	58
40	A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. PLoS ONE, 2016, 11, e0155917.	2.5	14
41	Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. Molecules and Cells, 2016, 39, 286-291.	2.6	47
42	On the Stability of Parainfluenza Virus 5 F Proteins. Journal of Virology, 2015, 89, 3438-3441.	3.4	6
43	Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry. Virology, 2015, 479-480, 518-531.	2.4	96
44	Membrane Anchoring of Epstein-Barr Virus gp42 Inhibits Fusion with B Cells Even with Increased Flexibility Allowed by Engineered Spacers. MBio, 2015, 6, .	4.1	6
45	Assembly and Architecture of the EBV B Cell Entry Triggering Complex. PLoS Pathogens, 2014, 10, e1004309.	4.7	68
46	The Epstein-Barr Virus (EBV) Glycoprotein B Cytoplasmic C-Terminal Tail Domain Regulates the Energy Requirement for EBV-Induced Membrane Fusion. Journal of Virology, 2014, 88, 11686-11695.	3.4	22
47	The Conserved Disulfide Bond within Domain II of Epstein-Barr Virus gH Has Divergent Roles in Membrane Fusion with Epithelial Cells and B Cells. Journal of Virology, 2014, 88, 13570-13579.	3.4	18
48	Activation of paramyxovirus membrane fusion and virus entry. Current Opinion in Virology, 2014, 5, 24-33.	5.4	120
49	Probing the Functions of the Paramyxovirus Glycoproteins F and HN with a Panel of Synthetic Antibodies. Journal of Virology, 2014, 88, 11713-11725.	3.4	9
50	Accelerated dissociation of IgE-Fcl μ RI complexes by disruptive inhibitors actively desensitizes allergic effector cells. Journal of Allergy and Clinical Immunology, 2014, 133, 1709-1719.e8.	2.9	122
51	Probing the paramyxovirus fusion (F) protein-refolding event from pre- to postfusion by oxidative footprinting. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2596-605.	7.1	44
52	Fusion Activation through Attachment Protein Stalk Domains Indicates a Conserved Core Mechanism of Paramyxovirus Entry into Cells. Journal of Virology, 2014, 88, 3925-3941.	3.4	76
53	Mutations in the Parainfluenza Virus 5 Fusion Protein Reveal Domains Important for Fusion Triggering and Metastability. Journal of Virology, 2013, 87, 13520-13531.	3.4	62
54	A soluble form of Epstein-Barr virus gH/gL inhibits EBV-induced membrane fusion and does not function in fusion. Virology, 2013, 436, $118-126$.	2.4	13

#	Article	IF	CITATIONS
55	An Engineered Disulfide Bond Reversibly Traps the IgE-Fc3–4 in a Closed, Nonreceptor Binding Conformation. Journal of Biological Chemistry, 2012, 287, 36251-36257.	3.4	10
56	Accelerated disassembly of IgE–receptor complexes by a disruptive macromolecular inhibitor. Nature, 2012, 491, 613-617.	27.8	89
57	Fusing structure and function: a structural view of the herpesvirus entry machinery. Nature Reviews Microbiology, 2011, 9, 369-381.	28.6	372
58	Structure of the Newcastle disease virus hemagglutinin-neuraminidase (HN) ectodomain reveals a four-helix bundle stalk. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14920-14925.	7.1	147
59	Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22641-22646.	7.1	141
60	Analysis of Epstein-Barr Virus Glycoprotein B Functional Domains via Linker Insertion Mutagenesis. Journal of Virology, 2009, 83, 734-747.	3.4	27
61	Structure of a trimeric variant of the Epstein–Barr virus glycoprotein B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2880-2885.	7.1	199
62	Cleavage and Secretion of Epstein-Barr Virus Glycoprotein 42 Promote Membrane Fusion with B Lymphocytes. Journal of Virology, 2009, 83, 6664-6672.	3.4	32
63	Class III viral membrane fusion proteins. Current Opinion in Structural Biology, 2009, 19, 189-196.	5.7	123
64	Structure of Epstein-Barr Virus Glycoprotein 42 Suggests a Mechanism for Triggering Receptor-Activated Virus Entry. Structure, 2009, 17, 223-233.	3.3	56
65	Conformational Flexibility in Immunoglobulin E-Fc3–4 Revealed in Multiple Crystal Forms. Journal of Molecular Biology, 2009, 393, 176-190.	4.2	35
66	Binding-Site Interactions between Epstein-Barr Virus Fusion Proteins gp42 and gH/gL Reveal a Peptide That Inhibits both Epithelial and B-Cell Membrane Fusion. Journal of Virology, 2007, 81, 9216-9229.	3.4	50
67	Hydrophobic Residues That Form Putative Fusion Loops of Epstein-Barr Virus Glycoprotein B Are Critical for Fusion Activity. Journal of Virology, 2007, 81, 9596-9600.	3.4	55
68	Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature, 2006, 439, 38-44.	27.8	374
69	Structural Changes in the Lectin Domain of CD23, the Low-Affinity IgE Receptor, upon Calcium Binding. Structure, 2006, 14, 1049-1058.	3.3	36
70	Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9217-9222.	7.1	78
71	Mutational Analyses of Epstein-Barr Virus Glycoprotein 42 Reveal Functional Domains Not Involved in Receptor Binding but Required for Membrane Fusion. Journal of Virology, 2004, 78, 5946-5956.	3.4	46
72	Structure of the Epstein-Barr Virus gp42 Protein Bound to the MHC Class II Receptor HLA-DR1. Molecular Cell, 2002, 9, 375-385.	9.7	138

#	Article	IF	CITATIONS
73	Structure of the Fc fragment of human IgE bound to its high-affinity receptor FclµRll±. Nature, 2000, 406, 259-266.	27.8	327
74	Structure of the Human IgE-Fc Cε3-Cε4 Reveals Conformational Flexibility in the Antibody Effector Domains. Immunity, 2000, 13, 375-385.	14.3	89
75	THE CRYSTAL STRUCTURE OF THE HUMAN HIGH-AFFINITY IgE RECEPTOR (FcεRIα). Annual Review of Immunology, 1999, 17, 973-976.	21.8	37
76	Structural basis for HLA-DQ binding by the streptococcal superantigen SSA. , 1999, 6, 123-129.		51
77	Structural Basis for Paramyxovirus-Mediated Membrane Fusion. Molecular Cell, 1999, 3, 309-319.	9.7	371